SecSonar.com

Rhythm Pharmaceuticals, Inc. (RYTM)

Rhythm Pharmaceuticals, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Rhythm Pharmaceuticals, Inc. (RYTM) is a Biotechnology company based in US with a market capitalization of $6.2B. Revenue grew 45.8% year-over-year and free cash flow was negative at -$116.6M. This page tracks RYTM's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 283 employees · IPO Oct 9, 2017

Valuation

Valuation & price

$90.52 · as of May 17, 2026 · -23.0% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

44.83

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$114$90.28$66.39Jul 25Dec 25Jul 26Jul 7, 25$66.39Jul 9, 25$89.00Jul 11, 25$86.70Jul 15, 25$89.36Jul 17, 25$90.68Jul 21, 25$88.63Jul 23, 25$87.81Jul 25, 25$86.45Jul 29, 25$85.63Jul 31, 25$85.23Aug 4, 25$90.24Aug 6, 25$90.01Aug 11, 25$94.31Aug 13, 25$97.86Aug 15, 25$97.61Aug 19, 25$97.19Aug 21, 25$101.68Aug 25, 25$99.20Aug 27, 25$102.30Aug 29, 25$103.15Sep 3, 25$101.69Sep 5, 25$102.12Sep 9, 25$101.44Sep 11, 25$97.92Sep 16, 25$95.52Sep 18, 25$98.54Sep 22, 25$99.00Sep 24, 25$96.91Sep 26, 25$99.16Sep 30, 25$100.99Oct 2, 25$97.23Oct 6, 25$97.86Oct 8, 25$100.23Oct 10, 25$100.82Oct 14, 25$105.20Oct 16, 25$111.18Oct 21, 25$107.15Oct 23, 25$109.12Oct 27, 25$111.55Oct 29, 25$113.89Oct 31, 25$113.76Nov 4, 25$104.99Nov 6, 25$98.49Nov 10, 25$97.63Nov 12, 25$97.92Nov 14, 25$99.41Nov 18, 25$100.51Nov 20, 25$100.66Nov 25, 25$108.75Nov 28, 25$109.09Dec 2, 25$101.39Dec 4, 25$105.70Dec 8, 25$105.18Dec 10, 25$104.77Dec 12, 25$113.56Dec 16, 25$112.45Dec 18, 25$111.73Dec 22, 25$112.88Dec 24, 25$112.27Dec 29, 25$112.55Jan 2, 26$105.01Jan 6, 26$99.42Jan 8, 26$97.46Jan 12, 26$104.89Jan 14, 26$113.34Jan 16, 26$101.63Jan 21, 26$105.95Jan 23, 26$102.87Jan 27, 26$105.53Jan 29, 26$103.70Feb 2, 26$108.99Feb 4, 26$107.97Feb 9, 26$103.97Feb 11, 26$98.47Feb 13, 26$98.07Feb 18, 26$101.30Feb 20, 26$99.78Feb 24, 26$98.65Feb 26, 26$98.07Mar 2, 26$94.94Mar 4, 26$91.00Mar 6, 26$93.52Mar 10, 26$93.01Mar 12, 26$91.15Mar 17, 26$87.68Mar 19, 26$90.31Mar 23, 26$84.65Mar 25, 26$84.62Mar 27, 26$75.82Mar 31, 26$86.97Apr 2, 26$86.29Apr 7, 26$86.66Apr 9, 26$86.13Apr 13, 26$86.81Apr 15, 26$87.81Apr 17, 26$88.69Apr 22, 26$85.18Apr 24, 26$85.70Apr 28, 26$84.18Apr 30, 26$81.36May 4, 26$85.58May 6, 26$96.61May 8, 26$94.17May 12, 26$91.31May 14, 26$93.63May 18, 26$86.84May 20, 26$90.64May 22, 26$87.84May 28, 26$92.98Jun 1, 26$87.87Jun 3, 26$84.71Jun 5, 26$86.40Jun 9, 26$87.86Jun 11, 26$87.66Jun 15, 26$89.70Jun 17, 26$95.83Jun 22, 26$101.39Jun 24, 26$107.55Jun 26, 26$109.84Jul 2, 26$114.17
$65.1452-week range$117.62
Loading valuation history…

Fundamentals

Key fundamentals

$6.2B

Market cap

45.8%

Revenue growth (YoY)

89.7%

Gross margin

-$116.6M

Free cash flow (USD)

-$142.5M

Net debt

Net cash position

6.5%

Share dilution

0/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$0.00FY 2017$0.00FY 2018$0.00FY 2019$0.00FY 2020$0.00FY 2021$3.2MFY 2022$23.6MFY 2023$77.4MFY 2024$130.1MFY 2025$189.8M
$0$189.8M

Free cash flow by year

2016 → 2025

FY 2016$-24.3MFY 2017$-29.6MFY 2018$-62.8MFY 2019$-126.1MFY 2020$-122.2MFY 2021$-151.4MFY 2022$-177.7MFY 2023$-136.2MFY 2024$-113.9MFY 2025$-116.6M
-$24.3M-$116.6M

Gross margin by year

2021 → 2025

FY 202181.0%FY 202291.0%FY 202388.0%FY 202489.7%FY 202589.7%
81.0%89.7%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

2

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 5, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventAnnual Meeting ResultsJun 25, 2026Filing
  • Insider sellInsider Sell $3.7M · 10b5-1 PlanTETRAULT LYNN A. · Director · $3.7MJun 24, 2026Filing
  • 8-K eventClinical Trial Data ReleasedJun 15, 2026Filing
  • Insider sellInsider Sell $428KGerman Christopher Paul · Corporate Controller & CAO · $428.1KMay 19, 2026Filing
  • 8-K eventEarnings ReleaseMay 5, 2026Filing
  • Quarterly report10-Q FiledMay 5, 2026Filing
  • 8-K eventBoard ChangesApr 3, 2026Filing

Questions

Frequently asked questions

What is Rhythm Pharmaceuticals, Inc.'s market cap?

Rhythm Pharmaceuticals, Inc. (RYTM) has a market capitalization of $6.2B.

What is RYTM's P/E ratio?

A meaningful P/E ratio is not available for RYTM — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is RYTM's price-to-book (P/B) ratio?

RYTM trades at 44.83 times book value per share.

Are insiders buying RYTM stock?

SEC Form 4 filings show no open-market insider buys at Rhythm Pharmaceuticals, Inc. in the last 90 days (2 sells).

Same arena

Related companies in Biotechnology

CNTA

Centessa Pharmaceuticals plc

$6.1B

PTCT

PTC Therapeutics, Inc.

$6.1B

PTGX

Protagonist Therapeutics, Inc.

$6.4B

TGTX

TG Therapeutics, Inc.

$5.9B

KYMR

Kymera Therapeutics, Inc.

$6.7B

LQDA

Liquidia Corporation

$5.5B

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.